Aura Biosciences, Inc. (AURA)
Data as of , from SEC Form 4 filings.
See up to 3 months of AURA. The 7-day demo opens the 1M and 3M ranges and puts AURA on your watchlist.
Start 7-day demoLatest AURA insider trades
Anthony S. Gibney - OfficerOpen-market sale$82K- Matrix Capital Management Company, LP - 10% OwnerOpen-market sale
About Aura Biosciences, Inc. (AURA)
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
- BOSTON, MA
- 113
- 2021
- XNAS
https://www.aurabiosciences.comSEC filings for AURA on EDGAR
AURA Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 10 | 1,265,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
AURA insider transactions (Form 4)
4840 Form 4 filings on record, the earliest from Oct 1, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Julie Person - Officer | Grant or award | Common Stock | 107,611 footnote F1 | $0.00 | - | |
| Julie Person - Officer | Grant or award | Stock Option (Right to Buy) | 212,389 | $0.00 | - | |
| ||||||
| Erica Kratz - Officer | Grant or award | Common Stock | 100,885 footnote F1 | $0.00 | - | |
| Erica Kratz - Officer | Grant or award | Stock Option (Right to Buy) | 199,115 | $0.00 | - | |
| ||||||
 Janet Jill Hopkins - Officer | Grant or award | Common Stock | 58,850 footnote F1 | $0.00 | - | |
| Janet Jill Hopkins - Officer | Grant or award | Stock Option (Right to Buy) | 116,150 | $0.00 | - | |
| ||||||
 Amy Elazzouzi - Officer | Grant or award | Common Stock | 23,540 footnote F1 | $0.00 | - | |
| Amy Elazzouzi - Officer | Grant or award | Stock Option (Right to Buy) | 46,460 | $0.00 | - | |
| ||||||
| Susan Abu-Absi - Officer | Grant or award | Common Stock | 134,513 footnote F1 | $0.00 | - | |
| Susan Abu-Absi - Officer | Grant or award | Stock Option (Right to Buy) | 265,487 | $0.00 | - | |
| ||||||
 Jeremy Bender | Grant or award | Common Stock | 30,000 footnote F1 | $0.00 | - | |
| Jeremy Bender | Grant or award | Stock Option (Right to Buy) | 60,000 | $0.00 | - | |
| ||||||
 Conor Kilroy - Officer | Grant or award | Common Stock | 14,858 footnote F1 | $0.00 | - | |
| ||||||
| Anthony S. Gibney - Officer | Open-market sale | Common Stock | 12,824 | $6.42 | $82K | |
 Teresa Marie Bitetti | Grant or award | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
| Teresa Marie Bitetti | Grant or award | Common Stock | 15,000 footnote F1 | $0.00 | - | |
| ||||||
| Sapna Srivastava | Grant or award | Common Stock | 15,000 footnote F1 | $0.00 | - | |
| Sapna Srivastava | Grant or award | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
| ||||||
| David Michael Johnson | Grant or award | Common Stock | 15,000 footnote F1 | $0.00 | - | |
| David Michael Johnson | Grant or award | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
| ||||||
| Antony C. Mattessich | Grant or award | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
| Antony C. Mattessich | Grant or award | Common Stock | 15,000 footnote F1 | $0.00 | - | |
| ||||||
| Natalie C. Holles - Officer | Grant or award | Common Stock | 600,118 footnote F1 | $0.00 | - | |
| Natalie C. Holles - Officer | Grant or award | Common Stock | 553,844 footnote F2 | $0.00 | - | |
| Natalie C. Holles - Officer | Grant or award | Stock Option (Right to Buy) | 2,169,103 | $0.00 | - | |
| ||||||
| Matrix Capital Management Company, LP - 10% Owner | Open-market sale | Common Stock, par value $0.00001 per share (Common Stock) | 6,922,870 | $5.64 | $39.04M | |
| Conor Kilroy - Officer | Open-market sale | Common Stock | 11,738 | $7.02 footnote F2 | $82K | |
| ||||||
| Conor Kilroy - Officer | Grant or award | Common Stock | 62,339 footnote F1 | $0.00 | - | |
| Conor Kilroy - Officer | Grant or award | Stock Option (Right to Buy) | 112,661 | $0.00 | - | |
| ||||||
| Anthony S. Gibney - Officer | Grant or award | Common Stock | 71,245 footnote F1 | $0.00 | - | |
| Anthony S. Gibney - Officer | Grant or award | Stock Option (Right to Buy) | 128,755 | $0.00 | - | |
| ||||||
| Los Pinos Elisabet de - Officer | Grant or award | Common Stock | 166,000 footnote F1 | $0.00 | - | |
| Los Pinos Elisabet de - Officer | Grant or award | Stock Option (Right to Buy) | 249,000 | $0.00 | - | |
| ||||||
 Mark Plavsic - Officer | Grant or award | Common Stock | 62,339 footnote F1 | $0.00 | - | |
| Mark Plavsic - Officer | Grant or award | Stock Option (Right to Buy) | 112,661 | $0.00 | - | |
| ||||||
| Janet Jill Hopkins - Officer | Grant or award | Common Stock | 89,056 footnote F1 | $0.00 | - | |
| Janet Jill Hopkins - Officer | Grant or award | Stock Option (Right to Buy) | 160,944 | $0.00 | - | |
| ||||||
| Amy Elazzouzi - Officer | Grant or award | Common Stock | 44,528 footnote F1 | $0.00 | - | |
| Amy Elazzouzi - Officer | Grant or award | Stock Option (Right to Buy) | 80,472 | $0.00 | - | |
| ||||||
| Conor Kilroy - Officer | Open-market sale | Common Stock | 12,079 | $5.05 footnote F2 | $61K | |
| ||||||
| Mark Plavsic - Officer | Open-market sale | Common Stock | 15,890 | $5.05 footnote F2 | $80K | |
| ||||||
| Janet Jill Hopkins - Officer | Open-market sale | Common Stock | 20,401 | $5.06 footnote F2 | $103K | |
| ||||||
| Amy Elazzouzi - Officer | Open-market sale | Common Stock | 8,549 | $5.06 footnote F2 | $43K | |
| ||||||
| Los Pinos Elisabet de - Officer | Open-market sale | Common Stock | 47,648 | $5.06 footnote F2 | $241K | |
| ||||||
| Amy Elazzouzi - Officer | Open-market sale | Common Stock | 1,581 | $4.86 | $8K | |
| Los Pinos Elisabet de - Officer | Open-market sale | Common Stock | 16,928 | $4.86 footnote F2 | $82K | |
| ||||||
| Janet Jill Hopkins - Officer | Open-market sale | Common Stock | 17,109 | $5.42 footnote F2 | $93K | |
| ||||||
| Amy Elazzouzi - Officer | Open-market sale | Common Stock | 896 | $6.35 | $6K | |
Item 2.02, 2.05, 5.02, 8.01, 9.01
Item 5.07
Item 5.02, 9.01
Item 5.07
Recent AURA Form 144 notices of proposed sale
1An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR |
AURA insider trading FAQ
What is the latest insider trade for AURA?
Aura Biosciences, Inc. (AURA) had 5 insider filings in the last 90 days, with the most recent on 2026-09-01. The full record for AURA runs to 40 Form 4 filings, the earliest from 2024-10-01. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying AURA stock?
No insider purchases of AURA were filed in the last 90 days.
How many insiders are selling AURA stock?
No insider sales of AURA were filed in the last 90 days. 21 sales are on record for this company.
Where can I see AURA SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects AURA Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Julie Person view on EDGAR
- - Erica Kratz view on EDGAR
- - Janet Jill Hopkins view on EDGAR
- - Amy Elazzouzi view on EDGAR
- - Susan Abu-Absi view on EDGAR
- - Jeremy Bender view on EDGAR
- - Conor Kilroy view on EDGAR
- - Anthony S. Gibney view on EDGAR
- - Teresa Marie Bitetti view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where AURA's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow AURA with a 7-day demo
- AURA on your watchlist
- Every AURA Form 4 filing on record
- Up to 3 months of AURA price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
